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BACKGROUND: A new diagnostic system, called one-step nucleic acid amplification (OSNA), has recently been designed to detect
cytokeratin 19 mRNA as a surrogate for lymph node metastases. The objective of this prospective investigation was to compare the
performance of OSNA with both standard hematoxylin and eosin (H&E) analysis and intensive histopathology in the detection of co-
lon cancer lymph node metastases. METHODS: In total, 313 lymph nodes from 22 consecutive patients with stage I, II, and III colon
cancer were assessed. Half of each lymph node was analyzed initially by H&E followed by an intensive histologic workup (5 levels of
H&E and immunohistochemistry analyses, the gold standard for the assessment of sensitivity/specificity of OSNA), and the other half
was analyzed using OSNA. RESULTS: OSNA was more sensitive in detecting small lymph node tumor infiltrates compared with H&E
(11 results were OSNA positive/H&E negative). Compared with intensive histopathology, OSNA had 94.5% sensitivity, 97.6% specificity,
and a concordance rate of 97.1%. OSNA resulted in an upstaging of 2 of 13 patients (15.3%) with lymph node-negative colon cancer af-
ter standard H&E examination. CONCLUSIONS: OSNA appeared to be a powerful and promising molecular tool for the detection of
lymph node metastases in patients with colon cancer. OSNA had similar performance in the detection of lymph node metastases
compared with intensive histopathologic investigations and appeared to be superior to standard histology with H&E. Most important,
the authors concluded that OSNA may lead to a potential upstaging of >15% of patients with colon cancer. Cancer 2012;118:6039-45.
VC 2012 American Cancer Society.
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INTRODUCTION
Approximately 20% to 25% of patients with lymph node-negative colon cancer will suffer from recurrent disease within 5
years.1-3 This phenomenon is explained in part by small lymph node tumor infiltrates, which remain undetected using
current histopathologic workup.4,5 Most commonly, only 1 level of hematoxylin and eosin (H&E) staining is performed
to assess lymph nodes in patients with colon cancer. However, this approach analyzes only a very small and arbitrarily
chosen part of the entire lymph node tissue and, thus, missing small tumor metastases is unavoidable. The suboptimal sen-
sitivity of H&E staining for the detection of lymph node metastases in patients with colorectal cancer is well known.4-7
The lack of an impeccable detection method of lymph node metastases remains a very unsettling problem for the oncolo-
gist, because potentially under-staged patients may not receive beneficial adjuvant chemotherapy and, thus, will have a
greater risk of local and distal recurrences as well as worse overall survival.8,9
Compared with standard H&E staining of lymph nodes in patients with colon cancer, it has been demonstrated that
multilevel sectioning and the use of immunohistochemistry (IHC) can improve the detection of small tumor infiltrates in
lymph nodes.4,10 Recently, a new diagnostic, semiautomatic system, called one-step nucleic acid amplification (OSNA),
was developed for the potential detection of lymph node metastases. OSNA is based on reverse transcription–loop-medi-
ated isothermal amplification (RT-LAMP)11 to amplify cytokeratin 19 (CK19) mRNA. CK19 is an epithelial marker,
which, when identified in lymph nodes from patients with colorectal cancer, is highly suggestive of the presence of lymph
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node metastases.12-14 OSNA was used previously for the
detection of breast cancer12-17 and gastric cancer18; how-
ever, currently, the data are very limited regarding the
detection of colon cancer lymph node metastases.19,20
The objective of the current investigation was to
compare the performance of OSNA versus both standard
H&E and intensive histopathologic analyses in the detec-
tion of colon cancer lymph node metastases. Our hypoth-
esis was that OSNA would provide better lymph node
staging in patients with colon cancer versus the current
standard (conventional H&E analysis) and would have
similar sensitivity and specificity for the detection of
lymph node metastases compared with intensive
histopathologic analysis using multilevel sectioning and
IHC.
MATERIALS AND METHODS
Patients
This study involved 22 consecutive patients with stage I
through III colon cancer. Patients with metastatic disease
were excluded from the study.
Study Design
The objective of the current prospective investigation was
to compare the performance of OSNA with the perform-
ance of both standard H&E and intensive histopathologic
analysis (multilevel sectioning and IHC) in the detection
of colon cancer lymph node metastases. An intensive his-
tologic workup (H&E plus IHC), as described below, was
considered the gold standard for assessing the sensitivity
and specificity of OSNA.
All included patients provided written informed
consent. The study was approved by the local ethical com-
mittee and was compliant with the Declaration of
Helsinki.
Analysis of Lymph Nodes
After patients underwent tumor resection, a pathologist
(A.Z.) who was present in the operating room received
and immediately processed the native specimen. Lymph
nodes were meticulously harvested from the pericolic fatty
tissue. Following the study protocol, lymph nodes >3
mm in greatest dimension were included into the study
for OSNA analysis as well as multilevel sectioning and
IHC. Lymph nodes were cut into 1-mm slices by a cutter
that was provided by Sysmex (Kobe, Japan). The slices for
OSNA were shock-frozen in liquid nitrogen and stored at
70C until molecular analysis was performed. The slices
for histopathologic workup were fixed in formalin. All
lymph nodes that measured<3 mm in greatest dimension
were completely embedded for conventional histopatho-
logic workup. The cutoff size of 3 mm was chosen for
technical reasons: If the lymph nodes are smaller than 3
mm, then it is almost impossible technically to slice them
into 4 pieces and perform further analyses as we did in the
current study.
The analysis of lymph nodes was described in detail
in the study protocol. Each lymph node was analyzed
separately, cut into 4 slices, and continuously labeled
a through d. Slices a and c were pooled together and
analyzed using OSNA, and slices b and d were subjected
to an intensive histologic workup (H&E and CK 19 IHC
staining on 5 levels for each of the 2 lymph node slices).
Intensive Histologic Work-Up
Slices b and d were fixed with neutral buffered formalde-
hyde and processed on paraffin blocks. One initial level
and additional levels with a 0.20-mm skip space were cut
from slices b and d until no remnant remained. From the
initial level and from the subsequent 4 levels, four 4-lm
sections were used for H&E staining and CK19 IHC
(DAKO, Glostrup, Denmark; 1:400 dilution). Thus, 5
H&E sections and 5 CK19 IHC sections were systemati-
cally prepared from each block. CK19 was chosen as the
target marker because it is both highly specific and sensi-
tive for the detection of colorectal cancer lymph node me-
tastases. In a recent publication by Yamamoto et al, CK19
was expressed in all 85 colorectal cancer specimens, and
most specimens (94%) had high expression.20 On the
basis of this strong expression of CK19, the use of other
markers was omitted, because this would have increased
the costs and potentially would have decreased the speci-
ficity of the assay (producing a higher rate of false-positive
results). According to the study protocol, lymph nodes
that harbored isolated tumor cells (0.2 mm in greatest
dimension) were considered negative.
One-Step Nucleic Acid Amplification
The OSNA method is based on the detection of CK19
mRNA as a marker for colorectal cancer cells. A cutoff
value of 250 mRNA copies/lL was used in the current
investigation. A result with a CK19 mRNA copy number
<250/lL was regarded as negative, and a copy number
250/lL was considered a positive result.
There is an association between the number of tu-
mor cells in the specimen and the OSNA result: the more
tumor cells present in a specimen, the faster the predeter-
mined threshold of positivity will be reached.13,20 The
amount of tumor tissue present in the specimen is deter-
mined by the rise time, eg, the time to exceed a predeter-
mined threshold of turbidity, which is caused by
magnesium pyrophosphate, a by-product that is released
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during the amplification. The higher the tumor load in
the specimen, the shorter the rise time will be and, thus,
the faster the threshold of turbidity will be reached.13,20
The determination of the cutoff level between positive
and negative results was described in and based on the
publications by Tsujimoto et al13 and Yamamoto et al.20
However, this cutoff level was established to detect micro-
metastases and macrometastases, while isolated tumor cells
fall below the threshold of sensitivity. Rapid mRNA
detection was achieved by homogenizing slices of the
dissected lymph nodes in 4 mL homogenizing buffer
(Lynorhag; Sysmex, Kobe, Japan) and directly amplifying
CK19 mRNA without prior extraction or purification of
nucleic acids (DNA and/or RNA). Lysates were prepared
according to the standard operating procedure of themanu-
facturer. OSNA analysis was performed with the ready-to-
use Lynoamp reaction kit on the RD-100i (Sysmex).
Approximately 40 to 45 minutes were used for the investi-
gation of 3 or 4 lymph nodes, including preparation and
amplification time. To avoid observer bias, the OSNA
analyses were done in a blinded fashion without knowledge
of findings from the intensive histologic workup.
Investigation of Discordant Cases
All discordant cases (OSNA-positive/histology-negative
or OSNA-negative/histology-positive) were analyzed fur-
ther with quantitative reverse-transcription-polymerase
chain reaction (qRT-PCR) using CK19 and carcinoem-
bryonic antigen (CEA) as described elsewhere.19 If the
qRT-PCR confirmed the OSNA result, then we con-
cluded that discordant findings were based on tissue allo-
cation bias. This means that the differences between the
intensive histologic workup and the OSNA analysis were
because some small tumor infiltrates were localized only
in the half of the lymph node that was analyzed either by
OSNA or by histology. Therefore, these cases were
excluded from the final analysis, because a comparison of
the 2 methods was not feasible.
RESULTS
In this prospective study, 313 lymph nodes from 22
consecutive patients with stage I to III colon cancer were
analyzed. There were 10 women and 12 men, and the
median patient age was 76 years (range, 55-88 years). The
median number of harvested lymph nodes per patient was
30 (range, 16-60 lymph nodes), and a median of 13
lymph nodes (range, 6-24 lymph nodes) were analyzed
using OSNA. Grading, tumor size, and tumor stage are
provided in Table 1.
Fifty-one lymph nodes were positive and 246 lymph
nodes negative with both OSNA and standard H&E (Ta-
ble 2). OSNA was more sensitive for detecting small tu-
mor infiltrates compared with H&E (11 OSNA-positive/
H&E-negative) (Table 2). Of those 11 lymph nodes, 1
harbored a micrometastasis, 5 harbored isolated tumor
cells, and 5 remained negative after multilevel sectioning
and IHC (Tables 2, 3).
Table 1. Tumor Description
Variable No. of Patients (%)
Total 22 (100)
Grade
1: Well differentiated 0 (0)
2: Moderately well differentiated 18 (81.8)
3: Poorly differentiated 4 (18.2)
4: Undifferentiated 0 (0)
Pathologic tumor classification
pT1 0 (0)
pT2 7 (31.8)
pT3 12 (54.5)
pT4 3 (13.6)
Stage
I 6 (27.3)
II 7 (31.8)
III 9 (40.9)
Table 2. Comparison of One-Step Nucleic Acid Amplification
With Standard Hematoxylin and Eosin Analysis (n ¼ 313)
Histology: First-Level H&E
Positive Negative
OSNA Macrometastasis Micrometastasis ITC No ITC
Positivea 51 0 0 11b
Negative 2b 0 3 246
Abbreviations: H&E, hematoxylin and eosin; ITC, isolated tumor cells;
OSNA, one-step nucleic acid amplification.
a OSNA positivity is defined as >250 cytokeratin 19 mRNA copies/lL.
bDiscordant cases.
Table 3. Comparison of One-Step Nucleic Acid Amplification
With Intensive Histologic Workup (n ¼ 313)
Histology: H&E and IHCa
Positive Negative
OSNA Macrometastasis Micrometastasis ITC No ITC
Positiveb 51 1 5c 5c
Negative 2c 3c 77 169
Abbreviations: H&E, hematoxylin and eosin; IHC, immunohistochemistry;
ITC, isolated tumor cells; OSNA, one-step nucleic acid amplification.
a Two lymph node slices with 5 levels each were analyzed with H&E and
IHC.
bOSNA positivity is defined as >250 cytokeratin 19 mRNA copies/lL.
cDiscordant cases.
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In 77 lymph nodes that were negative according to
OSNA, isolated tumor cells were identified using inten-
sive histopathologic workup (Table 3). When OSNA was
compared with intensive histopathologic workup, there
were 15 discordant cases (10 OSNA-positive/histology-
negative, 5 OSNA-negative/histology-positive). All dis-
cordant cases were analyzed further using qRT-PCR for
CK19 and CEA. In 6 cases (4 OSNA-positive/histology-
negative, 2 OSNA-negative/histology-positive), the dis-
cordant case investigation using qRT-PCR confirmed the
OSNA result; thus, we concluded that these 6 discordant
findings were based on tissue allocation bias (eg, tumor
infiltrates were present exclusively in the half of the lymph
node analyzed either by OSNA or by histology) (Table 4).
After excluding these 6 cases and comparing the results
from an intensive histopathologic workup, OSNA had a
sensitivity of 94.5% and a specificity of 97.6% to detect
lymph node metastases with a concordance rate of 97.1%.
Two initially lymph node-negative patients were
upstaged by OSNA (2 of 13 patients; 15.4%). One
patient who had a positive OSNA result (620 copies/lL)
had a micrometastasis identified only after multilevel sec-
tioning and IHC, whereas the initial H&E examination
was negative. The other patient who was upstaged had a
strongly positive OSNA evaluation (1800 copies/lL).
This finding was confirmed with qRT-PCR results that
were positive for both CK19 and CEA. However, the his-
tologic analysis was negative.
DISCUSSION
On the basis of the current prospective study, OSNA
appeared to be a new and powerful molecular tool for the
detection of lymph node macrometastases and microme-
tastases in our series of 22 consecutive patients with colon
cancer. The performance of OSNA was similar to that of
intensive histopathologic investigations and appeared to
be superior to current H&E analysis. Because OSNA
allows an analysis of the entire lymph node, the often
observed problem of sampling bias because of insuffi-
ciently analyzed material in standard H&E analyses can
be overcome in the future. Therefore, OSNA may
improve the staging of patients with colon cancer through
the detection of otherwise hidden tumor deposits.
A relevant proportion of patients who have lymph
node-negative colon cancer will develop local recurrences.1-
3,21 One contributing factor to this recurrence rate is the
lack of detection of small lymph node metastases using the
current H&E-based histopathologic assessment.7,22 The
current National Comprehensive Cancer Network
(NCCN) recommends adjuvant chemotherapy for all
patients with lymph node-positive disease.23 Therefore, it
is crucial to identify all patients who have positive lymph
nodes to decrease the risk of local and distant failure. In the
current investigation, OSNA appeared to improve the
detection of lymph nodemetastases. This improved staging
method may lead to better patient selection for adjuvant
chemotherapy and consecutively improved local and dis-
tant control as well as better overall survival.
The current study provides compelling evidence
that OSNA is both very sensitive and specific for the
assessment of lymph node metastases in patients with co-
lon cancer and is comparable to extensive histopathologic
workup using multilevel sectioning and IHC. Further-
more, it is crucial to bear in mind for the interpretation of
this study that only half of each lymph node was assessed
by OSNA, because it was essential to compare the new,
investigational OSNA method with both standard H&E
analyses and multilevel sectioning and IHC. The sensitiv-
ity of OSNA for the detection of small tumor infiltrates
may be even greater when an entire lymph node is sub-
jected to OSNA analysis. In OSNA-positive/histology-
negative cases, which were identified as negative in subse-
quent qRT-PCR analyses (and, thus, were classified as
false-positive), it is possible that the results actually were
true-positive, because prolonged contact between the ho-
mogenizing buffer and the sample may have had a nega-
tive impact on the quality of mRNA, which subsequently
may have been rendered undetectable.
In the current study, 1 macrometastasis remained
undetected by OSNA (Table 4). This macrometastasis
was largely necrotic, which explains the finding, because
no mRNA was available for amplification in the OSNA
analysis or qRT-PCR. However, as observed in our analy-
sis, such findings are rare and usually observed in large,
already macroscopically evident lymph node metastases
that do not require any molecular workup.
Table 4. Comparison of One-Step Nucleic Acid Amplification
With Intensive Histologic Workup After Discordant Case
Investigation (n ¼ 307)
Histology: H&E and IHCa
Positive Negative
OSNA Macrometastasis Micrometastasis ITC No ITC
Positiveb 51 1 4c 2c
Negative 1c 2c 77 169
Abbreviations: H&E, hematoxylin and eosin; IHC, immunohistochemistry;
ITC, isolated tumor cells; OSNA, one-step nucleic acid amplification.
a Two lymph nodes slices with 5 levels each were analyzed with H&E and
IHC.
bOSNA positivity is defined as >250 cytokeratin 19 mRNA copies/lL.
c Discordant cases.
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Currently, there is no universal standard of histopa-
thologic workup of lymph nodes in colorectal resection
specimens that will assure the detection of most if not all
embedded lymph node metastases. The latest guidelines
of the College of American Pathologists recommend sub-
mitting all grossly negative or equivocal lymph nodes in
their entirety, and routine assessment can be limited to
conventional histologic techniques.24 Because the College
of American Pathologists considers current data insuffi-
cient to recommend special measures for the detection of
small tumor infiltrates, neither multiple levels of paraffin
blocks nor the use of any ancillary techniques like IHC are
recommended currently for the routine examination of
lymph nodes.25
It appears evident that a simple analysis with H&E
is insufficient for the assessment of lymph nodes in
patients with colon cancer. It may be reasonable to argue
that all lymph nodes should be analyzed using extensive
histopathologic workup, including multilevel sectioning
and IHC, to have the best possible staging method. How-
ever, this is a very time-consuming approach. Conversely,
OSNA is a standardized, reproducible method and
appears to be a sensitive and specific diagnostic tool for
the detection of lymph node metastases in patients with
colon cancer that can be performed semiautomati-
cally.19,20 Also, a major advantage of OSNA compared
with qRT-PCR is that the latter requires RNA purifica-
tion, whereas OSNA analysis can be done directly from
the lysate. This results in a timely evaluation of the speci-
men using OSNA.
In the study by Yamamoto and colleagues,20 OSNA
was compared with histopathologic examination in 385
lymph nodes from 85 patients who had colorectal cancer.
Half of each lymph node was analyzed using OSNA, and
the other half was subjected to histologic workup. The
authors reported a high concordance rate between OSNA
and histologic examination of 0.97. However, Yamamoto
and colleagues did not use IHC as a gold standard but
used only H&E examination in the analysis of those 385
lymph nodes. Conversely, in our prospective study, all
lymph nodes were subjected to H&E analysis as well as
IHC in the comparison with OSNA.
Recently, Croner et al published their findings on
the use of OSNA to evaluate 184 lymph nodes from 184
patients with colorectal cancer.19 Similar to our investiga-
tion, those authors reported a high concordance rate
between histology and OSNA (95.7%) for macrometasta-
ses and micrometastases. Also, both sensitivity and speci-
ficity were approximately 95% in their investigation.
However, their report differs from the current study in
many ways: First, the investigation by Croner et al was ret-
rospective, whereas our study was entirely prospective.
Second, whereas Croner et al used 1 randomly chosen
lymph node for each patient with colorectal carcinoma, a
median of 13 lymph nodes per patient were analyzed
molecularly using OSNA in our study. Finally, surpris-
ingly, Croner et al did not identify any lymph nodes with
isolated tumor cells, which have been observed in up to
76% of immunohistochemically analyzed colorectal
lymph nodes in most comparable studies.2,7,26
The choice of the cutoff level between a positive and
negative OSNA result in the current study was based on
the publications by Tsujimoto et al13 and Yamamoto
et al.20 Yamamoto and colleagues used a cutoff value
between positive and negative lymph nodes from patients
with colorectal cancer based on the logarithmic midpoint
between the maximum value of the CK19 mRNA copy
number in lymph nodes from pN0 patients with 2 stand-
ard deviations from the average of CK19 mRNA copy
number in histopathologically positive lymph nodes.20 In
the study by Tsujimoto et al, the cutoff value for OSNA
also was set at 250 CK19 mRNA copies/lL based on 84
histopathologically negative lymph nodes. The mean
value of CK19 mRNA expression with 3 standard devia-
tions amounted to 250 CK19 mRNA copies/lL.13 This
cutoff level was established to detect micrometastases and
macrometastases. In most publications that tested OSNA
for the detection of lymph node micrometastases and
macrometastases, the cutoff was set at 250 CK19 mRNA
copies/lL.13,17,19,20 Although some of those investiga-
tions were performed in patients with breast cancer, the
results of the molecular analyses are transferable to the set-
ting of patients with colon cancer. Therefore, the cutoff
level of 250 copies of CK19 mRNA copies/lL also was
chosen for the current investigation.
Although OSNA is very sensitive for the detection
of colorectal cancer macrometastases and micrometasta-
ses, it must be emphasized that OSNA is not intended to
detect isolated tumor cells. Indeed, the cutoff chosen for
OSNA positivity (250 copies/lL) will not be reached if
only isolated tumor cells are present, as clearly reflected in
Table 4: Seventy-seven isolated tumor cells that were
detected immunohistochemically were negative in
OSNA. However, the prognostic implications of small tu-
mor infiltrates in lymph nodes from patients with colon
cancer are unknown and remain a matter of great
debate.5,23,27-30
In the current study, 2 patients who had lymph
node-negative results from an H&E analysis of 1 slice
potentially were upstaged using OSNA (2 of 13 patients;
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15.4%). However, 1 patient with a positive OSNA result
and a negative initial H&E examination had a micrometa-
stasis identified only after multilevel sectioning and IHC
were performed. The second patient had a strongly posi-
tive OSNA result (1800 copies/lL). This positive finding
was confirmed with qRT-PCR for both CK19 and CEA.
The histologic analysis, however, was negative. It could be
argued that this was a false-positive finding, because no
tumor cells were detected using either H&E or IHC; how-
ever, the confirmation of the positive OSNA result by
qRT-PCR analysis for both CEA and CK19 makes this
highly unlikely. Moreover, this finding may be explained
by tissue allocation bias, eg, the tumor cells were present
only in the half of the lymph node that was analyzed by
OSNA. Nonetheless, these results underline the impor-
tance and the potential of the OSNA assay as an improved
staging method for patients with colon cancer, because
the entire lymph node is analyzed with OSNA.
Still, we would like to highlight some difficulties
applying OSNA to colon cancer specimens. First, OSNA
currently relies on the analysis of fresh material. Although
OSNA may be used on formalin-fixed material in the
future, to date, this is not possible. Therefore, OSNA
requires the immediate availability of a pathologist for
lymph node harvesting, whereas formalin-fixed resection
specimens can by processed at any time. Isolating lymph
nodes from fresh tissue requires more time, diligence, and
experience than when performed on well fixed resection
specimens. However, the time spent for lymph node sam-
pling will be more than compensated during the analytic
process. Second, processing colorectal specimens for
OSNA requires extreme care to avoid tissue contamination,
a problem that usually can be resolved easily in conven-
tional microscopy. Colorectal tumors can be large and fri-
able; and, because CK19 is a panepithelial marker present
in normal colonic epithelium and primary tumors, con-
tamination of material for molecular analysis by dislodged
tissue fragments during specimen processing has to be
avoided. Third, care has to be taken to macroscopically dis-
tinguish lymph node metastasis from tumor spread into the
pericolic fatty tissue. One possible solution to circumvent
this problem would be to limit OSNA analysis to patients
with clinically lymph node-negative tumors. Finally, a
comparison of sensitivity for detecting micrometastases and
macrometastases between OSNA and RT-PCR would be
of interest. However, because the objective of the current
study was to compare OSNA with both H&E and IHC, a
further comparison between OSNA and RT-PCR was
beyond the scope of this investigation but should be per-
formed in future prospective studies.
In conclusion, based on the current prospective
investigation, OSNA appears to be a powerful and prom-
ising new molecular tool for the detection of lymph node
metastases in patients with colon cancer. The performance
of OSNA in detecting micrometastases and macrometa-
stases is similar to that of histopathologic investigations
and appears to be superior to standard histopathologic
workup with H&E. Because OSNA allows an analysis of
the whole lymph node, the problem of sampling bias and
undetected tumor deposits because of uninvestigated ma-
terial will be overcome in the future. Therefore, OSNA
may improve the staging of patients with colon cancer.
The interesting findings of our study should be cor-
roborated in a randomized controlled trial. The current
study indicates that patients with colon cancer should be
randomized to standard H&E analysis of lymph nodes
versus lymph node assessment using OSNA analysis.
Although the current findings suggest that OSNA is supe-
rior to standard H&E for the assessment of lymph nodes
in patients with colon cancer, a larger, prospective cohort
study will be necessary to provide further evidence.
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